Table 2 Comparison of clinical symptoms, laboratory findings and clinical outcomes of patients with COVID-19 in two groups (hypertensive and normotensive patients)

Fever

N (%)

• ≥38.5 c

78(44.3%)

125(29.6%)

• < 38.5

98(45.7%)

300(70.4%)

Cough

N (%)

103 (58.5%)

257(60.9%)

Dysphonia

N (%)

105(59.6%)

261(61.8%)

Chest pain

N (%)

38(21.6%)

107(25.3%)

Dizziness

N (%)

19(10.7%)

56(13.2%)

Headache

N (%)

56(31.8%)

153(36.2%)

Weakness

N (%)

90(51.4%)

232(55.1%)

Rhinorrhea

N (%)

20(11.3%)

41(9.7%)

Myalgia

N (%)

62(35.2%)

154(36.5%)

Test Sense

N (%)

21(11.9%)

51(12%)

Shortness of breath

N (%)

22(12.5%)

20(4.7%)

Diarrhea

N (%)

34(19.3%)

84(19.9%)

Vomiting

N (%)

53(30.2%)

136(32.3%)

 Leucocytes (× 109/L)

4–10

7.61 ± 7.45

6.26 ± 3.08

 Neutrophils (×109/L)

2–7

6.28 ± 0.65

5.23 ± .065

 Lymphocytes (×109/L)

0.8–4

2.09 ± 1.68

2.06 ± 1.68

 Platelets (×109/L)

125–450

164.2 ± 63.1

159.6 ± 75.2

 Hemoglobin (g/L)

115–150

15.67 ± 2.7

14.8 ± 2.8

 Hematocrit (%;)

33.35–50.8

44.15 ± 3.7

42.1 ± 4.3

 Albumin (g/L)

40–55

44.15 ± 7.8

41.5 ± 6.5

 Alt(U/L)

9–50

40.5 ± 24.6

39.6 ± 29.2

 Ast(U/L)

15–40

36.1 ± 26.2

32.2 ± 25.1

 Total bilirubin)

0–26

9.1 ± 3.1

8.6 ± 4.2

 Serum sodium (mmol/L)

137–147

135.6 ± 15.5

134.1 ± 18.1

 Serum potassium (mmol/L)

3.5–5.3

3.41 ± 2.4

3.31 ± 2.9

 Glucose (mmol/L)

70–140

5.99 ± 2.15

5.01 ± 1.96

 INR

0.85–1.15

1.41 ± 0.17

1.15 ± 0.13

 CRP (mg/L) d

0–10

41.2 ± 32.1

39.8 ± 31.2

Chest X-ray/CT findings

N (%)

• Normal

19(10.7%)

50(11.8%)

• Unilateral pneumonia

25(14.2%)

86(20.3%)

• Bilateral pneumonia

68 (38.6%)

156(36.9%)

• Multiple mottling and ground-glass opacity

64(36.5%)

159(31%)

 Increased hospital stays

N (%)

41(22.9%)

46(10.9%)

 Death

N (%)

16(9.1%)

25(5.9%)

 Readmission

N (%)

20(11.3%)

42(9.9%)